First Affiliated Hospital of Xi'an Jiaotong University
西安交通大学第一附属医院
Listed for 24 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at First Affiliated Hospital of Xi'an Jiaotong University
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌6 papers led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌12 papers led1 open trial led
- Hepatocellular carcinoma肝细胞癌122 papers led1 open trial led
- Stomach cancer胃癌69 papers led1 open trial led
- Hepatoblastoma肝母细胞瘤0 papers led
- Retinoblastoma视网膜母细胞瘤4 papers led
- Osteosarcoma骨肉瘤2 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤3 papers led
- Neuroblastoma神经母细胞瘤3 papers led
- Ewing sarcoma尤文肉瘤0 papers led
- Multiple myeloma多发性骨髓瘤8 papers led
- B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led
- Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症1 paper led
- Haemophilia A血友病 A1 paper led
- Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征0 papers led
- Takayasu arteritis大动脉炎2 papers led
- Hepatic echinococcosis肝包虫病0 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化8 papers led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症3 papers led
- Fabry disease法布雷病0 papers led
- Behçet disease白塞病0 papers led
- IgA nephropathyIgA 肾病7 papers led
- Primary biliary cholangitis原发性胆汁性胆管炎2 papers led
- Familial adenomatous polyposis家族性腺瘤性息肉病1 paper led
Not listed for: Chordoma, Aplastic anaemia, Beta thalassaemia, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 6 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
2 hospitals in Xi'an for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
- Phase
- Phase 2
- Started
- 2024-01
- Registry
- NCT05956587
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChongqing, Fuzhou, Guangzhou, Hangzhou, Linyi, Liuzhou, Nanchang, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingReduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
- Phase
- Phase 3
- Started
- 2024-03
- Registry
- NCT06239727
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 21 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Nanchang, Nanjing, Nanning, Shantou, Tianjin, Wuhan, Xi'an, Xiamen, Zhanjiang
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led6
- Inhibition of MAC30 exerts antitumor effects in nasopharyngeal carcinoma via affecting the Akt/GSK-3β/β-catenin pathway.
- 2,5-dimethyl celecoxib induces apoptosis and autophagy via activation of ROS/JNK axis in nasopharyngeal carcinoma cells.
- Long-term survival outcomes and adverse effects of nasopharyngeal carcinoma patients treated with IMRT in a non-endemic region: a population-based retrospective study.
- Oridonin inhibits epithelial-mesenchymal transition of human nasopharyngeal carcinoma cells by negatively regulating AKT/STAT3 signaling pathway.
- FBP1 enhances the radiosensitivity by suppressing glycolysis via the FBXW7/mTOR axis in nasopharyngeal carcinoma cells.
- RSPO2 silence inhibits tumorigenesis of nasopharyngeal carcinoma by ZNRF3/Hedgehog-Gli1 signal pathway.
All its trials on ClinicalTrials.gov, any status2
More papers found outside PubMed (not counted)18
- Additional file 1 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 2 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 3 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 4 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 5 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 6 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 7 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 2 of Long noncoding RNA LINC00930 promotes PFKFB3-mediated tumor glycolysis and cell proliferation in nasopharyngeal carcinoma
- Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 12 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.4%.
5 hospitals in Xi'an for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingAdebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC
- Phase
- Phase 2
- Started
- 2025-10
- Registry
- NCT07796113
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an
- RecruitingSKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07700667
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Harbin, Kunming, Luoyang, Nanchang, Nanjing, Nanning, Shantou, Shenyang, Shijiazhuang, Shiyan, Taiyuan, Tianjin, Xi'an, Zhengzhou
- RecruitingValue of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
- Phase
- Not given
- Started
- 2022-07
- Registry
- NCT05443841
Age not stated (registered criteria)
Led by Fudan University Shanghai Cancer Center; 8 listed hospitals as study sitesHefei, Nantong, Shanghai, Shijiazhuang, Taizhou (Jiangsu), Tianjin, Xi'an, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led12
- Relaxin 2 Suppresses Tumor Growth in Esophageal Squamous Cell Carcinoma EC9706 Cells Through Modulation of the STAT Signaling Pathway.
- HPV16 Enhances Radiosensitivity in Esophageal Squamous Cell Carcinoma by Promoting De Novo Fatty Acid Synthesis and Disulfidptosis.
- Circ_FNDC3B Promotes Cell Proliferation and Metastasis in Esophageal Squamous Cell Carcinoma via Regulating MAPK1 by Binding to miR-136-5p.
- Survival benefits of human papillomavirus 16 infection in patients with esophageal squamous cell carcinoma undergoing chemoradiotherapy: A retrospective cohort study.
- SP4 Facilitates Esophageal Squamous Cell Carcinoma Progression by Activating PHF14 Transcription and Wnt/Β-Catenin Signaling.
- Pristimerin exhibits anti-cancer activity by inducing ER stress and AKT/GSK3β pathway through increasing intracellular ROS production in human esophageal cancer cells.
- The AEG-1-USP10-PARP1 axis confers radioresistance in esophageal squamous cell carcinoma via facilitating homologous recombination-dependent DNA damage repair.
- SPARC expression in tumor microenvironment induces partial epithelial-to-mesenchymal transition of esophageal adenocarcinoma cells via cooperating with TGF-β signaling.
- Identification of m5C-related lncRNAs signature to predict prognosis and therapeutic responses in esophageal squamous cell carcinoma patients.
- An artificial neural network-based radiomics model for predicting the radiotherapy response of advanced esophageal squamous cell carcinoma patients: a multicenter study.
- MiR-671-5p sponging activity of circMMP1 promotes esophageal squamous cancer progression.
- Radiation induces NORAD expression to promote ESCC radiotherapy resistance via EEPD1/ATR/Chk1 signalling and by inhibiting pri-miR-199a1 processing and the exosomal transfer of miR-199a-5p.
All its trials on ClinicalTrials.gov, any status7
- Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC
- Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES)
- SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
- Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
- A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
- BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
- Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)
More papers found outside PubMed (not counted)22
- 2125P A phase II study of simmitinib in combination with liposomal irinotecan for second-line treatment of advanced esophageal squamous cell carcinoma
- 931P Update results of tislelizumab combined with chemotherapy or radiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (TINES): A randomized, open, phase II study
- KDM6B Promotes the Development, Progression and Metastasis of Oesophageal Cancer through Demethylation of Histones in the LDHA Promoter Region
- Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.
- Construction of eukaryotic expression vector of Apoptin-etag and TAT-Apoptin-etag and their effects on human esophageal squamous cell carcinoma in vitro
- Tislelizumab combined with chemotherapy or radiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (TINES): A randomized, open, phase II study.
- Additional file 1 of Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway
- Additional file 1 of Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth
- Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 2 of Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth
- Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Tumor marker index based on CYFRA21-1 and NSE is an important screening index for early-stage esophageal squamous cell carcinoma high-risk groups
- Additional file 1 of PABPC1-induced stabilization of IFI27 mRNA promotes angiogenesis and malignant progression in esophageal squamous cell carcinoma through exosomal miRNA-21-5p
- Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma
- MiR-4739 inhibits the malignant behavior of esophageal squamous cell carcinoma cells via the homeobox C10/vascular endothelial growth factor A/phosphatidylinositol 3-kinase/AKT pathway
- The oncogene EIF3c promotes esophageal squamous cell carcinoma tumorigenesis by inhibiting cell proliferation and inducing cell apoptosis
- The oncogene EIF3c promotes esophageal squamous cell carcinoma tumorigenesis by inhibiting cell proliferation and inducing cell apoptosis
- Comparative Study on the Esophageal Microflora of Different Tissue Types in Patients With Esophageal Squamous Cell Carcinoma
- First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.
- Repair of tracheoesophageal fistula with pedicled sternocleidomastoid muscle flap after minimally invasive esophagectomy: A case report
Cancer
Hepatocellular carcinoma
肝细胞癌Led 122 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.8%.
4 hospitals in Xi'an for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 4
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingReal-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study
- Phase
- Not given
- Started
- 2025-01
- Registry
- NCT07079150
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an
- RecruitingPhase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2025-11
- Registry
- NCT07176650
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07327034
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou
- RecruitingAnlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- Phase
- Phase 3
- Started
- 2023-05
- Registry
- NCT05862337
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led122
- p57 increases immunotherapy efficacy by promoting cGAS-STING-mediated innate sensing in hepatocellular carcinoma.
- FOXP1-transcriptionally regulated AEG-1 enhances tumor cell stemness to promote hepatocellular carcinoma radioresistance.
- Relationship between contrast-enhanced ultrasound combined with ultrasound resolution microscopy imaging and histological features of hepatocellular carcinoma.
- Dual-responsive magnetic vortex nanorings co-deliver lenvatinib and localized heat for synergistic activation of antitumor immunity.
- Copper-Based Nanotubes That Enhance Starvation Therapy Through Cuproptosis for Synergistic Cancer Treatment.
- Perioperative Changes in Serum Transaminase Levels: Impact on Postoperative Morbidity After Liver Resection of Hepatocellular Carcinoma.
- Perioperative Changes in Serum Transaminases Levels Predicts Long-Term Survival Following Liver Resection of Hepatocellular Carcinoma.
- A non-invasive nomogram for the prediction of poor prognosis of hepatocellular carcinoma based on the novel marker Interleukin-41.
- Development of a nomogram for predicting the long-term risk of hepatocellular carcinoma after antiviral treatment for hepatitis C.
- WWOX-mediated p53/SAT1 and NRF2/FPN1 axis contribute to toosendanin-induced ferroptosis in hepatocellular carcinoma.
- A novel hypoxia-induced lncRNA, SZT2-AS1, boosts HCC progression by mediating HIF heterodimerization and histone trimethylation under a hypoxic microenvironment.
- CCDC154 knockdown inhibits growth of liver cancer via suppressing expression of Snail.
- Perioperative dynamic changes of systemic inflammatory biomarkers predict tumor recurrence following curative-intent resection of hepatocellular carcinoma.
- Targeting DDOST improves the efficacy of lenvatinib and immunotherapy in hepatocellular carcinoma.
- Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma.
- A novel oncogene, leucine-rich repeat protein 1, mediates hypoxia-induced hepatocellular carcinoma progression.
- Sex disparity of liver cancer recurrence following surgery: sex-determining region Y gene promotes immunosuppressive microenvironment and favors metastasis.
- Migrasome-related prognostic signature TSPAN4 correlates with immune infiltrates and metabolic disturbances in hepatocellular carcinoma.
- Multi-omics profiling reveals downregulated tumor lysine metabolism reshaping the immune microenvironment and therapeutic responses in hepatocellular carcinoma.
- Identification of matrix stiffness-related molecular subtypes in HCC via integrating multi-omics analysis and machine learning algorithms.
- CAFs activated by YAP1 upregulate cancer matrix stiffness to mediate hepatocellular carcinoma progression.
- FOXM1-activated IGF2BP3 promotes cell malignant phenotypes and M2 macrophage polarization in hepatocellular carcinoma by inhibiting ferroptosis via stabilizing RRM2 mRNA in an m6A-dependent manner.
- High glucose facilitates hepatocellular carcinoma cell proliferation and invasion via WTAP-mediated HK2 mRNA stability.
- A ROS-mediated oxidation-O-GlcNAcylation cascade governs ferroptosis.
- C-Myc-activated FKBP4 promotes hepatocellular carcinoma cell proliferation and invasion by regulating the PHLPP1/AKT pathway.
- Development of a MVI associated HCC prognostic model through single cell transcriptomic analysis and 101 machine learning algorithms.
- Reprogrammed IDO-Induced Immunosuppressive Microenvironment Synergizes with Immunogenic Magnetothermodynamics for Improved Cancer Therapy.
- Intracellular Magnetic Hyperthermia Sensitizes Sorafenib to Orthotopic Hepatocellular Carcinoma Via Amplified Ferroptosis.
- Bioinspired Tumor Calcification-Guided Early Diagnosis and Eradication of Hepatocellular Carcinoma.
- Classification of Intrahepatic Cholangiocarcinoma into Perihilar Versus Peripheral Subtype.
- YAP1-activated ZNF131 promotes hepatocellular carcinoma cell proliferation through transcriptional regulation of PAIP1.
- Identification of pyroptosis-associated miRNAs in the immunoscape and prognosis of hepatocellular carcinoma.
- Establishment of nomogram prediction model of contrast-enhanced ultrasound and Gd-EOB-DTPA-enhanced MRI for vessels encapsulating tumor clusters pattern of hepatocellular carcinoma.
- USP40 promotes hepatocellular carcinoma progression through a YAP/USP40 positive feedback loop.
- FOXP2 suppresses the proliferation, invasion, and aerobic glycolysis of hepatocellular carcinoma cells by regulating the KDM5A/FBP1 axis.
- Laparoscopic right upper transversal hepatectomy: Strategies for right hepatic vein resection and reconstruction.
- Preoperative and postoperative MRI-based models versus clinical staging systems for predicting early recurrence in hepatocellular carcinoma.
- The significance of m6A RNA methylation regulators in diagnosis and subtype classification of HBV-related hepatocellular carcinoma.
- DNA damage response-related signatures characterize the immune landscape and predict the prognosis of HCC via integrating single-cell and bulk RNA-sequencing.
- NDC1 promotes hepatocellular carcinoma tumorigenesis by targeting BCAP31 to activate PI3K/AKT signaling.
- Hyaluronan-decorated copper-doxorubicin-anlotinib nanoconjugate for targeted synergistic chemo/chemodynamic/antiangiogenic tritherapy against hepatocellular carcinoma.
- Effect of surface modification on the distribution of magnetic nanorings in hepatocellular carcinoma and immune cells.
- Self-assembled copper-based nanoparticles for enzyme catalysis-enhanced chemodynamic/photodynamic/antiangiogenic tritherapy against hepatocellular carcinoma.
- Platelet-derived microparticles adoptively transfer integrin β3 to promote antitumor effect of tumor-infiltrating T cells.
- TSC/mTORC1 mediates mTORC2/AKT1 signaling in c-MYC-induced murine hepatocarcinogenesis via centromere protein M.
- Three molecular subtypes and a five-gene signature for hepatocellular carcinoma based on m7G-related classification.
- A Nomogram Based on Features of Ultrasonography and Contrast-Enhanced CT to Predict Vessels Encapsulating Tumor Clusters Pattern of Hepatocellular Carcinoma.
- Reversal of HMGA1-Mediated Immunosuppression Synergizes with Immunogenic Magnetothermodynamic for Improved Hepatocellular Carcinoma Therapy.
- METTL3-induced lncRNA GBAP1 promotes hepatocellular carcinoma progression by activating BMP/SMAD pathway.
- BCLAF1-induced HIF-1α accumulation under normoxia enhances PD-L1 treatment resistances via BCLAF1-CUL3 complex.
- Advances in experimental animal models of hepatocellular carcinoma.
- Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis.
- HIF-1α-activated TMEM237 promotes hepatocellular carcinoma progression via the NPHP1/Pyk2/ERK pathway.
- Identification and analysis of C17orf53 as a prognostic signature for hepatocellular carcinoma.
- The prognostic impact of tumor-infiltrating B lymphocytes in patients with solid malignancies: A systematic review and meta-analysis.
- HBx Modulates Drug Resistance of Sorafenib-Resistant Hepatocellular Carcinoma Cells.
- Conversion of primary liver cancer after targeted therapy for liver cancer combined with AFP-targeted CAR T-cell therapy: a case report.
- miR-144-3p represses hepatocellular carcinoma progression by affecting cell aerobic glycolysis via FOXK1.
- A Cox Nomogram for Assessing Recurrence Free Survival in Hepatocellular Carcinoma Following Surgical Resection Using Dynamic Contrast-Enhanced MRI Radiomics.
- Development and Validation of an α-Fetoprotein Tumor Burden Score Model to Predict Postrecurrence Survival among Patients with Hepatocellular Carcinoma.
- Extracellular Vesicles in Hepatocellular Carcinoma: Progress and Challenges in the Translation from the Laboratory to Clinic.
- Clinical significance of FBXO43 in hepatocellular carcinoma and its impact on tumor cell proliferation, migration and invasion.
- Liver transplantation for intrahepatic cholangiocarcinoma: a propensity score-matched analysis.
- Identification of ferroptosis and drug resistance related hub genes to predict the prognosis in Hepatocellular Carcinoma.
- A Bayesian Network Prediction Model for Microvascular Invasion in Patients with Intrahepatic Cholangiocarcinoma: A Multi-institutional Study.
- Integrative bioinformatics analysis of WDHD1: a potential biomarker for pan-cancer prognosis, diagnosis, and immunotherapy.
- Hypoxia-induced lncRNA MRVI1-AS1 accelerates hepatocellular carcinoma progression by recruiting RNA-binding protein CELF2 to stabilize SKA1 mRNA.
- Mitochondrial fission factor promotes cisplatin resistancein hepatocellular carcinoma.
- ASO Author Reflections: Postoperative Infectious Complications Worsen Long-Term Survival After Curative-Intent Resection for Hepatocellular Carcinoma.
- Postoperative Infectious Complications Worsen Long-Term Survival After Curative-Intent Resection for Hepatocellular Carcinoma.
- AZD4547 and the Alleviation of Hepatoma Cell Sorafenib Resistance via the Promotion of Autophagy.
- HCG15 is a hypoxia-responsive lncRNA and facilitates hepatocellular carcinoma cell proliferation and invasion by enhancing ZNF641 transcription.
- Matrix stiffness-induced upregulation of histone acetyltransferase KAT6A promotes hepatocellular carcinoma progression through regulating SOX2 expression.
- LncRNA SNHG5 promotes the proliferation and cancer stem cell-like properties of HCC by regulating UPF1 and Wnt-signaling pathway.
- Ubiquitin-specific protease 28 deubiquitinates TCF7L2 to govern the action of the Wnt signaling pathway in hepatic carcinoma.
- Identification of hepatocellular carcinoma subtypes based on PcG-related genes and biological relevance with cancer cells.
- Long Noncoding RNA BCYRN1 Recruits BATF to Promote TM4SF1 Upregulation and Enhance HCC Cell Proliferation and Invasion.
- Identification of CCL20 and LCN2 as Efficient Serological Tools for Detection of Hepatocellular Carcinoma.
- MicroRNA-455-3p functions as a tumor suppressor by targeting HDAC2 to regulate cell cycle in hepatocellular carcinoma.
- Comprehensive analysis of the amino acid metabolism-related gene signature for prognosis, tumor immune microenvironment, and candidate drugs in hepatocellular carcinoma.
- Utilization of elderly donors in liver transplantation for patients with hepatocellular carcinoma: A national retrospective cohort study of China.
- Hydrazide-manganese coordinated multifunctional nanoplatform for potentiating immunotherapy in hepatocellular carcinoma.
- Machine learning algorithms based on proteomic data mining accurately predicting the recurrence of hepatitis B-related hepatocellular carcinoma.
- Non-transplantable Recurrence After Resection for Transplantable Hepatocellular Carcinoma: Implication for Upfront Treatment Choice.
- Integrating bulk and single-cell RNA sequencing reveals cellular heterogeneity and immune infiltration in hepatocellular carcinoma.
- Hypoxia-driven miR-1307-3p promotes hepatocellular carcinoma cell proliferation and invasion by modulating DAB2 interacting protein.
- Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma.
- Role of Lipogenesis Rewiring in Hepatocellular Carcinoma.
- The HN1/HMGB1 axis promotes the proliferation and metastasis of hepatocellular carcinoma and attenuates the chemosensitivity to oxaliplatin.
- TRIM62 silencing represses the proliferation and invasion and increases the chemosensitivity of hepatocellular carcinoma cells by affecting the NF-κB pathway.
- The value of hepatobiliary phase in EOB-MRI in predicting hypervascularization outcome of non-hypervascular hypointense lesions in high-risk patients for hepatocellular carcinoma.
- Novel role of LINC01013/miR-6795-5p/FMNL3 axis in the regulation of hepatocellular carcinoma stem cell features.
- ASO Author Reflections: Multi-institutional Development and External Validation of a Nomogram for Prediction of Extrahepatic Recurrence After Curative-Intent Resection for Hepatocellular Carcinoma.
- Multi-Institutional Development and External Validation of a Nomogram for Prediction of Extrahepatic Recurrence After Curative-Intent Resection for Hepatocellular Carcinoma.
- Tumor Necrosis Impacts Prognosis of Patients Undergoing Curative-Intent Hepatocellular Carcinoma.
- ASO Author Reflections: Hepatocellular Carcinoma-Related Tumor Necrosis is Associated with Worse Long-Term Outcomes.
- Linc01559 Served as a Potential Oncogene and Promoted Resistance of Hepatocellular Carcinoma to Oxaliplatin by Directly Sponging miR-6783-3p.
- Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4-B1: a pilot study.
- Prognosis of liver transplantation: Does postoperative ileus matter?
- Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.
- HIF-1α-activated long non-coding RNA KDM4A-AS1 promotes hepatocellular carcinoma progression via the miR-411-5p/KPNA2/AKT pathway.
- Matrix stiffness modulates hepatic stellate cell activation into tumor-promoting myofibroblasts via E2F3-dependent signaling and regulates malignant progression.
- Circ-CSPP1 knockdown suppresses hepatocellular carcinoma progression through miR-493-5p releasing-mediated HMGB1 downregulation.
- Nucleolar protein 6 promotes cell proliferation and acts as a potential novel prognostic marker for hepatocellular carcinoma.
- A novel signature based on pairwise PD-1/PD-L1 signaling pathway genes for predicting the overall survival in patients with hepatocellular carcinoma.
- Hypoxia-induced cofilin 1 promotes hepatocellular carcinoma progression by regulating the PLD1/AKT pathway.
- Development and validation of a robust epithelial-mesenchymal transition (EMT)-related prognostic signature for hepatocellular carcinoma.
- HIPK3 Circular RNA Promotes Metastases of HCC Through Sponging miR-338-3p to Induce ZEB2 Expression.
- Prediction of tumor recurrence by α-fetoprotein model after curative resection for hepatocellular carcinoma.
- Hepatocellular-cholangiocarcinoma with sarcomatous change: Clinicopathological features and outcomes.
- Identification and validation of redox-immune based prognostic signature for hepatocellular carcinoma.
- Saikosaponin-d increases radiation-induced apoptosis of hepatoma cells by promoting autophagy via inhibiting mTOR phosphorylation.
- Performance of SPINK1 and SPINK1-based diagnostic model in detection of hepatocellular carcinoma.
- Long non-coding RNA MAPKAPK5-AS1/PLAGL2/HIF-1α signaling loop promotes hepatocellular carcinoma progression.
- Early Versus Late Recurrence of Hepatocellular Carcinoma After Surgical Resection Based on Post-recurrence Survival: an International Multi-institutional Analysis.
- A study on the inconsistency of arterial phase hypervascularity detection between contrast-enhanced ultrasound using sonazoid and gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid magnetic resonance imaging of hepatocellular carc
- Long noncoding RNA highly upregulated in liver cancer promotes the progression of hepatocellular carcinoma and attenuates the chemosensitivity of oxaliplatin by regulating miR-383-5p/vesicle-associated membrane protein-2 axis.
- Biological features, gene expression profile, and mechanisms of drug resistance of two- and three-dimensional hepatocellular carcinoma cell cultures.
- Safety and efficacy study: Short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona Clinical Liver Cancer stage 0-B1 hepatocellular carcinoma.
- NT157 Inhibits HCC Migration via Downregulating the STAT3/Jab1 Signaling Pathway.
- Evaluation of the Efficacy and Toxicity of Radiotherapy for Type III-IV Portal Vein Tumor Thrombi.
- Cellular senescence in hepatocellular carcinoma induced by a long non-coding RNA-encoded peptide PINT87aa by blocking FOXM1-mediated PHB2.
Chinese-language papers (not in the count)5
- [Angio-associated migratory cell protein is highly expressed in hepatocellular carcinoma and promotes tumor cell invasion and metastasis].
- [Overexpression of miR-607 inhibits hepatocellular carcinoma cell growth and metastasis by down-regulating TRPC5].
- [Regulatory effect of small nuclear ribonucleoprotein-associated protein B on proliferation and metastasis of liver cancer cells].
- [Regulatory effects of LIM kinase 1 on the proliferation and metastasis of hepatocellular carcinoma cells].
- [Effect of splenectomy on the risk of hepatocellular carcinoma development among patients with liver cirrhosis and portal hypertension: a multi-institutional cohort study].
All its trials on ClinicalTrials.gov, any status28
- Real-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study
- Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment
- Camrelizumab Utilization on Patients With Advanced Liver Cancer
- Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence
- ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer
- ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma
- Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver Transplantation
- ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer
- A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization
- A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
- Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
- A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
- Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
- Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
- Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
- Neoadjuvant HAIC for Resectable Hepatocellular Carcinoma Beyond Milan Criteria
- HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
- Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation
- Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
- A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
- HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC
- A Study to Evaluate SHR-1210 in Subjects With Advanced HCC
- T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients
Cancer
Stomach cancer
胃癌Led 69 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.7%.
5 hospitals in Xi'an for stomach cancer211 hospitals in China for stomach cancer
Open trials with this hospital 8
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingClinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer
- Phase
- Phase 4
- Started
- 2024-07
- Registry
- NCT06499610
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an
- RecruitingClinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07385703
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 64 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou
- RecruitingRadical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
- Phase
- Phase 3
- Started
- 2026-12
- Registry
- NCT07789184
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an
- RecruitingStudy of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Phase
- Phase 3
- Started
- 2025-02
- Registry
- NCT06731478
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou
- RecruitingSON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2025-02
- Registry
- NCT06873659
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan, Lanzhou, Nanjing, Shanghai, Xi'an
- RecruitingFeasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer
- Phase
- Phase 3
- Started
- 2025-06
- Registry
- NCT07029269
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Guangzhou, Hangzhou, Lanzhou, Xi'an
- RecruitingAssessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07127822
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Harbin, Qingdao, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou
- RecruitingA Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2022-01
- Registry
- NCT05150691
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led69
- The mediating role of postoperative blood glucose in the relationship between body composition and overall survival in non-diabetic gastric cancer patients.
- Analyses of single-cell RNA sequencing uncover the role of intratumoral Helicobacter pylori in shaping tumor progression and immunity in gastric cancer.
- A multi-omics prognostic model of cuproptosis affects the prognosis of stomach adenocarcinoma.
- USP26 Promotes Cell Proliferation of Gastric Cancer by Stabilizing c-Myc.
- Investigation of the gastric toxicity induced by exposure to tri-isobutyl phosphate.
- Preoperative Glycosylated Hemoglobin A1C Impacts Long-Term Outcomes Following Curative-Intent Resection of Nonfunctional Gastroenteropancreatic Neuroendocrine Tumors.
- Construction and effect evaluation of perioperative nursing model for gastric cancer patients based on enhanced recovery after surgery (ERAS) concept.
- A fully annotated pathology slide dataset for early gastric cancer and precancerous lesions.
- Clinical outcomes and cost-effectiveness analysis of robotic and endoscopic cooperative surgery for treating gastric submucosal tumors: a longitudinal nested cohort study.
- Quantifying Tumor Budding: Implications for Prognosis in Gastric Adenocarcinoma.
- The spatiotemporal associations between esophageal and gastric cancers provide evidence for its joint endoscopic screening in China: a population-based study.
- Gastric cancer patient-derived organoids model for the therapeutic drug screening.
- Single-cell RNA sequencing to map tumor heterogeneity in gastric carcinogenesis paving roads to individualized therapy.
- Dapagliflozin suppressed gastric cancer growth via regulating OTUD5 mediated YAP1 deubiquitination.
- Xenograft and organoid models in developing precision medicine for gastric cancer (Review).
- Efficacy, safety, and advantages of magnetic anchor-guided endoscopic submucosal dissection vs conventional endoscopic submucosal dissection: A retrospective paired cohort study.
- Preoperative anemia: impact on short- and long-term outcomes following curative-intent resection of gastroenteropancreatic neuroendocrine tumors.
- miR-181-5p/KLHL5 Promoted Proliferation and Migration of Gastric Cancer Through Activating METTL3-Mediated m6A Process.
- Preparation and identification of a fluorescent probe with CsPbBr3perovskite quantum dots and CD44v6 specific peptide for gastric cancer imaging.
- Identification of miRNA, lncRNA and circRNA associated with gastric cancer metabolism through sequencing and bioinformatics analysis.
- Expression patterns of E2Fs identify tumor microenvironment features in human gastric cancer.
- The clinicopathological characteristics of gastric cancer and precancerous conditions in gastric DLBCL and MALT lymphoma patients: a multi-center retrospective study.
- CT features of calcified micro-gastric gastrointestinal stromal tumors: a case series.
- USP14-mediated deubiquitination of SIRT1 in macrophage promotes fatty acid oxidation amplification and M2 phenotype polarization.
- Study on TFF1 and PALB2 gene variants associated with gastric carcinoma risk in the Chinese Han population.
- The factors influencing the accuracy of pre-operative endoscopic ultrasonography assessment in endoscopic treatments for gastrointestinal tumors.
- SLC39A10 promotes malignant phenotypes of gastric cancer cells by activating the CK2-mediated MAPK/ERK and PI3K/AKT pathways.
- The comparison of long-term oncological outcomes and complications after proximal gastrectomy with double tract reconstruction versus total gastrectomy for proximal gastric cancer.
- Advanced lung cancer inflammation index (ALI) predicts prognosis of patients with gastric cancer after surgical resection.
- A novel 450-nm laser-mediated sinoporphyrin sodium-based photodynamic therapy induces autophagic cell death in gastric cancer through regulation of the ROS/PI3K/Akt/mTOR signaling pathway.
- The nuclear-localized GHR is involved in the cell proliferation of gastric cancer, and pegvisomant may be an important potential drug to inhibit the proliferation of gastric cancer cells.
- Collagen type IV alpha 1 (COL4A1) silence hampers the invasion, migration and epithelial-mesenchymal transition (EMT) of gastric cancer cells through blocking Hedgehog signaling pathway.
- Comprehensive Analysis of Alternative Splicing in Gastric Cancer Identifies Epithelial-Mesenchymal Transition Subtypes Associated with Survival.
- Inhibition of MDFI attenuates proliferation and glycolysis of Helicobacter pylori-infected gastric cancer cells by inhibiting Wnt/β-catenin pathway.
- Integration of exosomal miR-106a and mesothelial cells facilitates gastric cancer peritoneal dissemination.
- Effect of Self-Transcendence Theory Combined with Comprehensive Nursing Intervention under Tumor Nutrition Education on Symptom Improvement, Nutritional Status, and Positive Psychology of Elderly Patients with Gastric Cancer.
- PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance.
- CircRNA-ABCB10 promotes gastric cancer progression by sponging miR-1915-3p to upregulate RaC1.
- Inhibition of Ras protein activator like 2 produces antitumor effects in gastric cancer via the suppression of YAP1 activation.
- Characteristics of the immunogenicity and tumor immune microenvironment in HER2-amplified lung adenocarcinoma.
- Analysis of immune status in gastric adenocarcinoma with different infiltrating patterns and origin sites.
- The genetic polymorphisms in the SP4 gene and the risk of gastric cancer.
- SERPINA5 promotes tumour cell proliferation by modulating the PI3K/AKT/mTOR signalling pathway in gastric cancer.
- Diagnostic value of carcinoembryonic antigen combined with cytokines in serum of patients with colorectal cancer.
- Efficacy and safety of laparoscopic distal D2 radical gastrectomy for advanced gastric cancer patients.
- High level of TXNDC9 predicts poor prognosis and contributes to the NF-κB-regulated metastatic potential in gastric cancer.
- Deubiquitinase USP13 promotes the epithelial-mesenchymal transition and metastasis in gastric cancer by maintaining Snail protein.
- Endoscopic submucosal dissection treatment of metachronous early gastric adenocarcinoma in a case with diffuse large B-cell lymphoma.
- Predictive value of neutrophil-to-lymphocyte ratio for distant metastasis in gastric cancer patients.
- Clinical outcomes and functional analysis of third space robotic and endoscopic cooperative surgery versus laparoscopic wedge resection for gastric submucosal tumours: a propensity score-matched study.
- A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer.
- A high level of lncFGD5-AS1 inhibits epithelial-to-Mesenchymal transition by regulating the miR-196a-5p/SMAD6/BMP axis in gastric Cancer.
- Activation of Toll-like receptor 2 enhances peripheral and tumor-infiltrating CD8+ T cell cytotoxicity in patients with gastric cancer.
- The circACC1/miR-29c-3p/FOXP1 network plays a key role in gastric cancer by regulating cell proliferation.
- miR-4677-3p participates proliferation and metastases of gastric cancer cell via CEMIP-PI3K/AKT signaling pathway.
- Oxidative stress activates NORAD expression by H3K27ac and promotes oxaliplatin resistance in gastric cancer by enhancing autophagy flux via targeting the miR-433-3p.
- A signature of 14 immune-related gene pairs predicts overall survival in gastric cancer.
- Flap endonuclease 1 (FEN1) as a novel diagnostic and prognostic biomarker for gastric cancer.
- Effects of miR-362 in Regulating the Proliferation, Invasion and Apoptosis of Gastric Cancer by Inhibiting the Expression of Tumor-Promoting Factor PRDM2.
- LINC01436 Inhibited miR-585-3p Expression and Upregulated MAPK1 Expression to Promote Gastric Cancer Progression.
- Knockdown of DDX46 suppresses the proliferation and invasion of gastric cancer through inactivating Akt/GSK-3β/β-catenin pathway.
- Deubiquitinase PSMD7 promotes the proliferation, invasion, and cisplatin resistance of gastric cancer cells by stabilizing RAD23B.
- Long non-coding RNA MSC-AS1 facilitates the proliferation and glycolysis of gastric cancer cells by regulating PFKFB3 expression.
- Cancer-associated fibroblast infiltration in gastric cancer: the discrepancy in subtypes pathways and immunosuppression.
- Intraoperative localization of gastrointestinal tumors by magnetic tracer technique during laparoscopic-assisted surgery (with video).
- A new endoscopic technique for specific gastrointestinal stromal tumors: a retrospective cohort study.
- LINC00963/miR-4458 regulates the effect of oxaliplatin in gastric cancer by mediating autophagic flux through targeting of ATG16L1.
- A nomogram combining plasma fibrinogen and systemic immune‑inflammation index predicts survival in patients with resectable gastric cancer.
- Value of preoperative gastroscopic carbon nanoparticles labeling in patients undergoing laparoscopic radical gastric cancer surgery.
Chinese-language papers (not in the count)2
All its trials on ClinicalTrials.gov, any status35
- Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer
- Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer
- Comparison of the Efficiency Between Intraoperative and Postoperative Hyperthermic Intraperitoneal Chemotherapy With Docetaxel Combine Oxaliplatin in Patients With Advanced Gastric Cancer
- Effectiveness of Managing Suspected Metastasis and Progress Using Plasma D-dimer Testing in Gastric Cancer Patients
- A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma
- A New Method: the Third Space Robotic and Endoscopic Cooperative Surgery (TS-RECS)
- Laparoscopic Endoscopic Cooperative Surgery in the Treatment of Gastric Stromal Tumors
- Comparison of Open Laparoscopic and Robotic Surgery in Gastric Cancer Resection.
- A Randomized Controlled Clinical Study on the Application of the Third Space in the Operation of Gastric Submucosal Tumor
- Learning Curve for Robot-Assisted Gastrectomy in Gastric Cancer
- Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
- Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer
- Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
- Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
- A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis
- HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
- Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
- BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
- Incidence of Pancreatic Fistula After Radical Gastrectomy
- Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer
- Roux-en-Y vs. Roux-en-Y+ Pouch for D2 Total Gastrectomy
Cancer
Hepatoblastoma
肝母细胞瘤Led no English-language PubMed papers on hepatoblastoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Xi'an for hepatoblastoma86 hospitals in China for hepatoblastoma
No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Cancer
Retinoblastoma
视网膜母细胞瘤Led 4 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 1.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Xi'an for retinoblastoma176 hospitals in China for retinoblastoma
No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- Bringing p53 Back: A Prion-Powered Attack on Retinoblastoma.
- Knockdown of the Long Noncoding RNA TUG1 Suppresses Retinoblastoma Progression by Disrupting the Epithelial-Mesenchymal Transition.
- Long Non-Coding RNA TP53TG1 Upregulates SHCBP1 to Promote Retinoblastoma Progression by Sponging miR-33b.
- A nano-predator of pathological MDMX construct by clearable supramolecular gold(I)-thiol-peptide complexes achieves safe and potent anti-tumor activity.
Cancer
Osteosarcoma
骨肉瘤Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Xi'an for osteosarcoma570 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Earlier papers (2016–2020)8
- PTPN14, a target gene of miR-4295, restricts the growth and invasion of osteosarcoma cells through inactivation of YAP1 signalling.
- Downregulation of Adrenomedullin Leads to the Inhibition of the Tumorigenesis via VEGF Pathway in Human and Nude Mice Osteosarcoma Models.
- A nomogram for determining the disease-specific survival in Ewing sarcoma: a population study.
- Development and validation of a nomogram for osteosarcoma-specific survival: A population-based study.
- CXCL8 promotes the invasion of human osteosarcoma cells by regulation of PI3K/Akt signaling pathway.
- MiR-598: A tumor suppressor with biomarker significance in osteosarcoma.
- miR-504 promotes tumour growth and metastasis in human osteosarcoma by targeting TP53INP1.
- High expression of TRIM29 (ATDC) contributes to poor prognosis and tumor metastasis by inducing epithelial‑mesenchymal transition in osteosarcoma.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 3 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.6%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Xi'an for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- CT features of calcified micro-gastric gastrointestinal stromal tumors: a case series.
- Clinical outcomes and functional analysis of third space robotic and endoscopic cooperative surgery versus laparoscopic wedge resection for gastric submucosal tumours: a propensity score-matched study.
- A new endoscopic technique for specific gastrointestinal stromal tumors: a retrospective cohort study.
Earlier papers (2016–2020)5
- Clinical feasibility and safety of third space robotic and endoscopic cooperative surgery for gastric gastrointestinal stromal tumors dissection : A new surgical technique for treating gastric GISTs.
- Clinicopathological and Prognostic Significance of Expression of B-Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (BMI-1) Gene and Protein in Gastrointestinal Stromal Tumors.
- Gastrointestinal stromal tumors: Fibrinogen levels are associated with prognosis of patients as blood-based biomarker.
- Prognostic value of fibrinogen and D-dimer-fibrinogen ratio in resectable gastrointestinal stromal tumors.
- Laparoscopic Versus Open Resection of Gastric Gastrointestinal Stromal Tumors Larger Than 5 cm: A Single-Center, Retrospective Study.
All its trials on ClinicalTrials.gov, any status2
Cancer
Neuroblastoma
神经母细胞瘤Led 3 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
12 hospitals in Xi'an for neuroblastoma321 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Diabetes influences the fusion of autophagosomes with lysosomes in SH-SY5Y cells and induces Aβ deposition and cognitive dysfunction in STZ-induced diabetic rats.
- Identification of USP29 as a key regulator of nucleotide biosynthesis in neuroblastoma through integrative analysis of multi-omics data.
- A Novel pH-Sensitive Multifunctional DNA Nanomedicine: An Enhanced and Harmless GD2 Aptamer-Mediated Strategy for Guiding Neuroblastoma Antitumor Therapy.
Earlier papers (2016–2020)1
Cancer
Ewing sarcoma
尤文肉瘤Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Xi'an for Ewing sarcoma134 hospitals in China for Ewing sarcoma
No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 8 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.5%.
- Open trials led
- 0
- recruiting or about to
4 hospitals in Xi'an for multiple myeloma175 hospitals in China for multiple myeloma
Open trials with this hospital 5
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
- Phase
- Phase 1
- Started
- 2025-12
- Registry
- NCT07179679
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChengde, Chongqing, Guangzhou, Nanchang, Nanchong, Nanjing, Shanghai, Suzhou, Xi'an
- RecruitingA Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06083207
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Nanjing, Nanning, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an, Xuzhou
- RecruitingA Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 2
- Started
- 2021-02
- Registry
- NCT04634552
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Suzhou, Tianjin, Xi'an
- Not yet recruitingClinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07569757
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou
- Not yet recruitingA Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Registry
- NCT07090954
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led8
- Sex and Gender in Myeloid and Lymphoblastic Leukemias and Multiple Myeloma: From Molecular Mechanisms to Clinical Outcomes.
- Deciphering N-Glycosylation Dynamics of Serum Monoclonal Immunoglobulins in Multiple Myeloma via EThcD-sceHCD-MS/MS.
- Exploring natural killer cell-related biomarkers in multiple myeloma: a novel nature killer cell-related model predicting prognosis and immunotherapy response using single-cell study.
- Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma.
- The effect of marital status on the survival of patients with multiple myeloma.
- Cold Atmospheric Plasma Suppressed MM In Vivo Engraftment by Increasing ROS and Inhibiting the Notch Signaling Pathway.
- Study on the Relationship Between the Expression of B Cell Mature Antigen and the Classification, Stage, and Prognostic Factors of Multiple Myeloma.
- Efficacy and cost of G-CSF derivatives for prophylaxis of febrile neutropenia in lymphoma and multiple myeloma patients underwent autologous hematopoietic stem cell transplantation.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status7
- The Diagnostic Pattern and Prognosis of Multiple Myeloma Patients With Myocardial Amyloidosis Were Evaluated by NMR Based Metabolomics
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma
- A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
- A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma
Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Xi'an for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia
No open trial on B-cell acute lymphoblastic leukaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
Blood disorders
Haemophagocytic lymphohistiocytosis
噬血细胞性淋巴组织细胞增生症Led 1 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Xi'an for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis
No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
More papers found outside PubMed (not counted)1
Blood disorders
Haemophilia A
血友病 ALed 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Xi'an for haemophilia A132 hospitals in China for haemophilia A
No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Blood disorders
Atypical haemolytic uraemic syndrome
非典型溶血性尿毒症综合征Led no English-language PubMed papers on atypical haemolytic uraemic syndrome in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Xi'an for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome
No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Takayasu arteritis
大动脉炎Led 2 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 1.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Xi'an for Takayasu arteritis100 hospitals in China for Takayasu arteritis
No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Other diseases
Hepatic echinococcosis
肝包虫病Led no English-language PubMed papers on hepatic echinococcosis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Xi'an for hepatic echinococcosis44 hospitals in China for hepatic echinococcosis
No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 8 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
10 hospitals in Xi'an for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led8
- Magnetic resonance imaging of focal organizing pneumonia: differential diagnosis with peripheral lung carcinoma.
- Exercise improves pulmonary fibrosis and neurological symptoms via S100A12 inhibition.
- PIEZO1 mediates periostin+ myofibroblast activation and pulmonary fibrosis in mice.
- The Reparative Effect of FOXM1 in Pulmonary Disease.
- Plasma genome-wide mendelian randomization identifies potentially causal genes in idiopathic pulmonary fibrosis.
- Genetic association of circulating C-reactive protein levels with idiopathic pulmonary fibrosis: a two-sample Mendelian randomization study.
- The role of PD-1/PD-L1 axis in idiopathic pulmonary fibrosis: Friend or foe?
- Transcriptome Classification Reveals Molecular Subgroups in Idiopathic Pulmonary Fibrosis.
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 3 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Xi'an for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Activating mitofusins interrupts mitochondrial degeneration and delays disease progression in SOD1 mutant amyotrophic lateral sclerosis.
- Comparative assessment of blood Metal/metalloid levels, clinical heterogeneity, and disease severity in amyotrophic lateral sclerosis patients.
- Characteristics of serum metabolites in sporadic amyotrophic lateral sclerosis patients based on gas chromatography-mass spectrometry.
Earlier papers (2016–2020)9
- Causal effects of serum metabolites on amyotrophic lateral sclerosis: A Mendelian randomization study.
- Dominant Heterogeneity of Upper and Lower Motor Neuron Degeneration to Motor Manifestation of Involved Region in Amyotrophic Lateral Sclerosis.
- Dissociated lower limb muscle involvement in amyotrophic lateral sclerosis and its differential diagnosis value.
- Decremental Responses to Repetitive Nerve Stimulation in Amyotrophic Lateral Sclerosis.
- Measuring the validation of assessing the non-dominant-hand function by ALSFRS-r in Chinese ALS patients.
- Urinary Extracellular Domain of Neurotrophin Receptor p75 as a Biomarker for Amyotrophic Lateral Sclerosis in a Chinese cohort.
- Spread Direction and Prognostic Factors in Limb-Onset Sporadic Amyotrophic Lateral Sclerosis.
- Sympathetic Skin Response in Amyotrophic Lateral Sclerosis.
- Hyperintensity of the corticospinal tract on FLAIR: A simple and sensitive objective upper motor neuron degeneration marker in clinically verified amyotrophic lateral sclerosis.
Other diseases
Fabry disease
法布雷病Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
3 hospitals in Xi'an for Fabry disease80 hospitals in China for Fabry disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
- Phase
- Not given
- Started
- 2025-11
- Registry
- NCT07187440
Age 7 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Behçet disease
白塞病Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Xi'an for Behçet disease139 hospitals in China for Behçet disease
No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
IgA nephropathy
IgA 肾病Led 7 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.9%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Xi'an for IgA nephropathy300 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led7
- Exploring the mediating role of immune cells in the pathogenesis of IgA nephropathy through the inflammatory axis of gut microbiota from a genomic perspective.
- Humoral immune responses primed by the alteration of gut microbiota were associated with galactose-deficient IgA1 production in IgA nephropathy.
- Serum Phosphorus Might Be a Predictor of Kidney Disease Progression in IgA Nephropathy.
- Spectrum of biopsy-proven kidney diseases in northwest China: a review of 30 years of experiences.
- Chimeric Fusion between Clostridium Ramosum IgA Protease and IgG Fc Provides Long-Lasting Clearance of IgA Deposits in Mouse Models of IgA Nephropathy.
- Epidemiological characteristics and pathological changes of primary glomerular diseases.
- Renal deposition and clearance of recombinant poly-IgA complexes in a model of IgA nephropathy.
Earlier papers (2016–2020)3
All its trials on ClinicalTrials.gov, any status5
- SodiUm Restriction by Behavioral Intervention
- A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
- A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- A Study of Telitacicept for IgA Nephropathy (TELIGAN)
- Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led 2 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
4 hospitals in Xi'an for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07282353
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou
- RecruitingSeladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- Phase
- Phase 3
- Started
- 2023-09
- Registry
- NCT06051617
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Shanghai, Urumqi, Wuhan, Xi'an, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status2
Other diseases
Familial adenomatous polyposis
家族性腺瘤性息肉病Led 1 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 1.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Xi'an for familial adenomatous polyposis74 hospitals in China for familial adenomatous polyposis
No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Other linked evidence
Getting in touch
Name card to show staff or a driver
西安交通大学第一附属医院
First Affiliated Hospital of Xi'an Jiaotong University
西安
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR Wikidata
First Affiliated Hospital of Xi'an Jiao Tong University; he First Affiliated Hospital of Xi'an Jiaotong University; First Affiliated Hospital of Xian Jiao Tong University; First Affiliated Hospital of Xi'an JiaoTong University; First Affiliated Hospital of Xian Jiaotong University